BMO Capital raises bristol-myers squibb's target price to $53.
September 29th, GleAnn | BMO Capital: BMO Capital: raised bristol-myers squibb's target price from $48 to $53, maintaining a 'market perform' rating.
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60
Daily short sale tracking: Ambev SA's short volume increased by 4 million, with a short sale ratio of 10%
Ambev SA(ABEV.US) ranked top of the list had the largest change in short volume (4.72 million shares), and the short volume ratio of Carnival(CUK.US) reached 39.75%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
US stocks close | US PCE inflation cools down, S&P Nasdaq falls but Dow hits new high; China concept index surges 24% for the whole week, jd.com hits fourteen-month high.
US PCE inflation cooling solidifies the confidence of the Fed in rate cuts, but US stocks fell in the afternoon, with nvidia dropping nearly 4% at one point. China's stimulus policies drove the Chinese concept index up by 4%, nio inc rose by nearly 13%, pan-European stock indexes and German stocks hit new highs for two consecutive days, luxury goods stocks rose again. The Dow, S&P, and Nasdaq have all risen for three consecutive weeks, with two China-focused ETFs achieving the best weekly gains in history.
Express News | The Food and Drug Administration (FDA) of the USA has approved Bristol-Myers Squibb's Cobenfy (xanomeline).
J&J Releases Encouraging Data on Talvey Combination Therapies
Bristol-Myers Squibb Options Spot-On: On September 27th, 99,897 Contracts Were Traded, With 833.89K Open Interest
On September 27th ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 99,897 options for the day, of which put options accounted for 23.47% of the total
Unusual Options Activity: UGI, TSLA and Others Attract Market Bets, UGI V/OI Ratio Reaches 197.4
EST Sep 27th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Sector Update: Health Care Stocks Mixed Late Afternoon
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
La FDA Aprueba Un Medicamento Con Un Nuevo Mecanismo De Acción Para El Tratamiento De La Esquizofrenia
US Equity Indexes Mixed as Treasury Yields Slip After Investors Weigh Easing in Inflation
Bristol-Myers Squibb Potential Scalp Psoriasis Treatment Meets Targets
Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns
Express News | Bristol-Myers Squibb (BMY): (Clinical trial results show) TYK-2 deforming inhibitor Sotyktu outperforms placebo on all endpoints.
Express News | Bristol-Myers Squibb Co -Safety Profile in Psoriatyk Scalp Was Consistent With Established Safety Profile of Sotyktu
Express News | Bristol-Myers Squibb Co - Primary Endpoint Met With Significant Improvement in Ss-Pga Response
Express News | Bristol Myers Squibb Presents New Data From Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
FDA Approves New Bristol Myers Squibb Schizophrenia Drug